The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndrome

Contributed by: PR Newswire

Tags

LUNDBECK-asedeb-ODD

More Like This

European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin

Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease

Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026

Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

BioArctic receives Orphan Drug Designation for exidavnemab the US

News Aktuell logo

GRÜNENTHAL RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR TEGACORAT FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY